Skip to main content

Caissa Capital Management ltd.'s Form 4 filing

Avalo Therapeutics, Inc. (AVTX) · filed May 8, 2023

Accession no.
0001929354-23-000007
Filed
May 8, 2023
Trade date
May 4-8, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market purchases total $69.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Caissa Capital Management ltd.CIK 000192935410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 4, 2023Common StockPPurchaseAcquired+15,000$2.79F2+$41,8501,332,700Indirect
May 5, 2023Common StockPPurchaseAcquired+5,000$2.88F3+$14,4001,337,700Indirect
May 8, 2023Common StockPPurchaseAcquired+5,000$2.62F4+$13,1001,342,700Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)